EGFR and non-small cell lung carcinoma: retrospectively evaluated the survival rate of 10 patients with advanced NSCLC who underwent salvage surgery after EGFR-TKI neoadjuvant therapy and found that 70% of patients have consistent clinical and pathological staging.